HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Satoru Takahashi Selected Research

1-O-hexyl-2,3,5-trimethylhydroquinone

12/2002Effects of antioxidant 1-O-hexyl-2,3,5-trimethylhydroquinone or ascorbic acid on carcinogenesis induced by administration of aminopyrine and sodium nitrite in a rat multi-organ carcinogenesis model.
2/2002Chemoprevention of 2-amino-1-methyl-6-phenylimidazo- [4,5-b]pyridine-induced colon carcinogenesis by 1-O-hexyl-2,3,5-trimethylhydroquinone after initiation with 1,2-dimethylhydrazine in F344 rats.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Satoru Takahashi Research Topics

Disease

152Neoplasms (Cancer)
12/2022 - 01/2002
104Prostatic Neoplasms (Prostate Cancer)
12/2022 - 01/2002
44Carcinogenesis
07/2021 - 02/2002
29Neoplasm Metastasis (Metastasis)
06/2022 - 09/2005
27Breast Neoplasms (Breast Cancer)
02/2022 - 12/2002
24Carcinoma (Carcinomatosis)
01/2022 - 02/2005
21Adenocarcinoma
02/2022 - 02/2002
16Inflammation (Inflammations)
01/2022 - 12/2002
14Fibrosis (Cirrhosis)
12/2021 - 12/2002
13Renal Cell Carcinoma (Grawitz Tumor)
03/2021 - 05/2005
13Urinary Bladder Neoplasms (Bladder Cancer)
01/2021 - 11/2008
12Overactive Urinary Bladder (Overactive Bladder)
01/2022 - 01/2006
11Hyperplasia
01/2021 - 07/2006
10Hepatocellular Carcinoma (Hepatoma)
01/2022 - 09/2002
9Infections
01/2022 - 07/2009
9Disease Progression
11/2020 - 03/2004
8Urinary Incontinence
01/2022 - 12/2007
8Pancreatic Neoplasms (Pancreatic Cancer)
01/2022 - 12/2015
7Stress Urinary Incontinence
04/2022 - 08/2006
7Prostatic Hyperplasia (Benign Prostatic Hyperplasia)
01/2021 - 01/2006
6Rupture
05/2022 - 07/2007
6Colonic Neoplasms (Colon Cancer)
02/2022 - 03/2011
6Adenoma (Adenomas)
05/2019 - 01/2009
5Body Weight (Weight, Body)
03/2022 - 05/2009
5Colorectal Neoplasms (Colorectal Cancer)
03/2022 - 10/2005
5Nocturia
01/2022 - 01/2006
5Alcoholic Fatty Liver
12/2021 - 04/2011
5Diabetes Mellitus
08/2020 - 06/2005
5Proteinuria
01/2020 - 10/2003
5Hyperglycemia
01/2018 - 08/2006
5Cardiovascular Diseases (Cardiovascular Disease)
01/2012 - 02/2008
4Dermatitis
12/2022 - 12/2019
4Psoriasis (Pustulosis Palmaris et Plantaris)
12/2022 - 01/2016
4Fatty Liver
09/2021 - 12/2015
4Insulin Resistance
09/2021 - 08/2016
4Seizures (Absence Seizure)
09/2021 - 07/2008
4Pain (Aches)
09/2021 - 10/2003
4Hypoxia (Hypoxemia)
01/2021 - 11/2006
4Fibrosarcoma
01/2021 - 08/2011
4Focal Segmental Glomerulosclerosis (Glomerulosclerosis, Focal)
01/2020 - 01/2018

Drug/Important Bio-Agent (IBA)

37Proteins (Proteins, Gene)FDA Link
03/2022 - 06/2002
34AndrogensIBA
12/2022 - 06/2002
31Androgen Receptors (Androgen Receptor)IBA
12/2022 - 06/2002
24Transcription Factors (Transcription Factor)IBA
01/2022 - 05/2003
23Messenger RNA (mRNA)IBA
02/2022 - 02/2002
18Hormones (Hormone)IBA
06/2022 - 02/2003
17Estrogen ReceptorsIBA
06/2019 - 09/2003
14Biomarkers (Surrogate Marker)IBA
03/2022 - 07/2014
14DNA (Deoxyribonucleic Acid)IBA
01/2021 - 12/2007
13CytokinesIBA
12/2021 - 06/2009
13Pharmaceutical PreparationsIBA
07/2021 - 02/2008
12Glucose (Dextrose)FDA LinkGeneric
09/2020 - 06/2005
9Biological ProductsIBA
07/2021 - 02/2006
8MicroRNAs (MicroRNA)IBA
01/2022 - 11/2011
8Reactive Oxygen Species (Oxygen Radicals)IBA
01/2022 - 12/2013
7EnzymesIBA
09/2021 - 06/2006
7Estrogens (Estrogen)FDA Link
01/2019 - 09/2003
7Immunoglobulin G (IgG)IBA
09/2015 - 03/2002
72- amino- 1- methyl- 6- phenylimidazo(4,5- b)pyridineIBA
08/2015 - 02/2002
7AntigensIBA
10/2010 - 09/2003
6Docetaxel (Taxotere)FDA Link
06/2022 - 02/2005
6Amino AcidsFDA Link
03/2022 - 04/2011
6ErbB Receptors (EGF Receptor)IBA
06/2021 - 11/2006
6Prostate-Specific Antigen (Semenogelase)IBA
01/2021 - 12/2006
6MafB Transcription FactorIBA
01/2020 - 01/2011
6Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
01/2019 - 11/2006
6benzocycloheptapyridineIBA
08/2015 - 02/2002
5AntibodiesIBA
01/2022 - 03/2002
5AntioxidantsIBA
12/2021 - 02/2002
5Gap Junction beta-1 ProteinIBA
12/2021 - 08/2007
5Insulin (Novolin)FDA Link
09/2021 - 10/2010
5Indicators and Reagents (Reagents)IBA
08/2021 - 02/2003
5Immune Checkpoint InhibitorsIBA
03/2021 - 01/2020
5Interleukin-17 (Interleukin 17)IBA
01/2021 - 02/2014
5Estradiol (Delestrogen)FDA LinkGeneric
11/2020 - 04/2003
5Cyclin D1IBA
02/2020 - 11/2009
5Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
01/2018 - 12/2003
5Testosterone (Sustanon)FDA Link
02/2017 - 04/2003
5Progesterone Receptors (Progesterone Receptor)IBA
11/2016 - 10/2008
4CholesterolIBA
05/2022 - 01/2018
4TamoxifenFDA LinkGeneric
03/2022 - 06/2016
4taxaneIBA
02/2022 - 05/2015
4Polysaccharides (Glycans)IBA
01/2022 - 10/2003
4Fluorouracil (Carac)FDA LinkGeneric
01/2022 - 09/2009
4GemcitabineFDA Link
01/2022 - 12/2007
4CaspasesIBA
07/2021 - 05/2009
4acetovanillone (apocynin)IBA
01/2021 - 11/2013
4Prednisolone (Predate)FDA LinkGeneric
01/2021 - 09/2003
4LuteolinIBA
01/2021 - 12/2015
4N- (4- ((5- (hydroxy(phenyl)methyl)pyrrolidin- 2- yl)methyl)phenyl)- 4- oxo- 4,6,7,8- tetrahydropyrrolo(1,2- a)pyrimidine- 6- carboxamideIBA
01/2021 - 01/2018
4AsbestosIBA
10/2020 - 07/2015
4Interleukin-6 (Interleukin 6)IBA
10/2020 - 12/2012

Therapy/Procedure

69Therapeutics
12/2022 - 02/2002
24Castration
06/2022 - 02/2003
14Drug Therapy (Chemotherapy)
02/2022 - 02/2005
10Prostatectomy (Retropubic Prostatectomy)
10/2014 - 01/2002
7Radiotherapy
04/2022 - 11/2008
7Chemoprevention
07/2021 - 02/2002
5Transplantation
01/2019 - 12/2011
4Aftercare (After-Treatment)
01/2022 - 12/2007